恶性葡萄胎患者化疗前后血清IL-2、SIL-2R和外周血B细胞和T淋巴细胞亚群检测的临床意义

目的:探讨了恶性葡萄胎患者化疗前后血清IL-2、SIL-2R和外周血B细胞及T淋巴细胞亚群水平及临床意义.方法:分别应用放射免疫分析、ELISA法和单克隆抗体法对32例恶性葡萄胎患者进行了血清IL-2、SIL-2R和外周血B细胞及T淋巴细胞亚群进行了检测,并与35名正常健康人作比较.结果:恶性葡萄胎患者在化疗前血清SIL-2R和B细胞数均非常显著地高于正常人(P＜0.01),而IL-2、CD3、CD4、CD4/CD8比值则显著地低于正常人组(P＜0.01),经化疗后6个月,与正常人比较仍有显著性差异(P＜0.05).结论:恶性葡萄胎患者是一种自身调节免疫异常的疾病.

Clinical Significance of Measurement of Changes of Serum IL-2, SIL-2R Level B Lymphocyte Number and T-cell Subsets After Chemotherapy in Patients with Malignant Hydatidiform Mole

Objective To study the clinical significance of changes of serum IL-2,SIL-2R level,peripheral blood B lymphocyte number and T-cell subsets after chemotherapy in patients with malignant hydatidiform mole.Methods Serum IL-2(with RIA) SIL-2R level(with ELISA) and peripheral blood B lymphocytes number as well as T subsets(with monoclonal antibody technique) were measured both before and after chemo therapy in 32 patients with malignant hydatidiform mole as well as in 35 controls.Results Before chemotherapy serum SIL-2R level and B lymphocyte were significantly higher in the patients than those in controls(P<0.01),while the serum IL-2 level CD3,CD4,CD4/CD8 were significantly lower(P<0.01).Six months after chemotherapy the levels changed markedly toward normal,but remained significantly different from those in controls(P<0.05).Conclusion Abnormal immuno-regulation were present in patients with malignant mole.